Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | 257 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines... ► Artikel lesen | |
20.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
16.05. | eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast | 376 | ACCESS Newswire | MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
13.05. | eXoZymes reports Q1 results | 2 | Seeking Alpha | ||
12.05. | eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today | 270 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
12.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
07.05. | eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST | 316 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines,... ► Artikel lesen | |
EXOZYMES Aktie jetzt für 0€ handeln | |||||
06.05. | eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health | 266 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier... ► Artikel lesen | |
25.04. | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
21.04. | eXoZymes Inc.: Bringing clarity and precision to the cell-free space by introducing exozymes | 1 | GlobeNewswire (USA) | ||
12.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 842 | ACCESS Newswire | New to The Street debuts its inaugural restaurant segment featuring BlackBarn with owner and chef John Doherty NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / New to The Street, a leading financial... ► Artikel lesen | |
11.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie's Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President T | 514 | ACCESS Newswire | BlackBarn Restaurant NYC on 26th street The premiere restaurant segment with Owner and Head Chef John Doherty NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / New to The Street, a leading... ► Artikel lesen | |
11.04. | New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presiden | 411 | ACCESS Newswire | New Segment "Market Bites" Debuts with Chef John Doherty of BlackBarn Showcasing the Culinary Side of Business Leadership NEW YORK CITY, NEW YORK / ACCESS Newswire / April 11, 2025 / New to The Street... ► Artikel lesen | |
10.04. | eXoZymes Inc.: BioClick - an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant | 2 | GlobeNewswire (USA) | ||
02.04. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
02.04. | eXoZymes appoints new chief commercial officer | 1 | Investing.com | ||
02.04. | eXoZymes GAAP EPS of -$0.89 | 2 | Seeking Alpha | ||
02.04. | eXoZymes Inc.: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO | 143 | GlobeNewswire (Europe) | Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus... ► Artikel lesen | |
02.04. | eXoZymes Inc.: eXoZymes Provides Fourth Quarter and Full Year 2024 Update | 238 | GlobeNewswire (Europe) | Management to Host Conference Call Today at 4:30PM Eastern Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that... ► Artikel lesen | |
31.03. | EXOZYMES INC. - 10-K, Annual Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,552 | -0,65 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
VALNEVA | 2,422 | +1,85 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
EPIGENOMICS | 0,610 | -10,29 % | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/13.06.2025/13:00... ► Artikel lesen | |
NOVAVAX | 5,640 | +0,68 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
4SC | 0,520 | +1,96 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,116 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
AAP IMPLANTATE | 1,790 | +5,29 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
SANGAMO THERAPEUTICS | 0,455 | -0,52 % | Sangamo stock holds Buy rating at H.C. Wainwright on Fabry therapy data | ||
MAINZ BIOMED | 1,370 | -3,52 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
INFLARX | 0,690 | +1,69 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
INTELLIA THERAPEUTICS | 9,160 | +9,26 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
COSCIENS BIOPHARMA | 2,840 | -2,74 % | COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders | TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) ("COSCIENS" or the "Company"), a life sciences company developing and commercializing a diversified... ► Artikel lesen | |
VAXART | 0,387 | -0,26 % | Vaxart wird vom Nasdaq ausgesetzt und plant Berufung gegen Delisting-Entscheidung |